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Abstract
To examine local and systemic oxidative status of lung cancer (LC) and oxidant effects of radiotherapy (RT), this study
evaluated antioxidants and markers of oxidative and nitrosative stress in bronchoalveolar lavage (BAL) fluid and in the blood
of 36 LC patients and 36 non-cancer controls at baseline and during and after RT for LC. LC patients had higher baseline
serum urate, plasma nitrite and lower serum oxidized proteins than controls (p 0.016, pB0.001 and p 0.027,
respectively), but BAL fluid oxidative stress markers were similar. RT tended to raise some antioxidants, however, significant
increases were seen in serum urate, conjugated dienes and TBARS (p 0.044, p 0.034 and p 0.004, respectively)
3 months after RT. High urate at baseline may compensate against the oxidative stress caused by LC. RT shifts the oxidant/
antioxidant balance towards lipid peroxidation, although the antioxidant defense mechanisms of the body appear to
counteract the increased oxidative stress rather effectively.
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Abbreviations: BAL, bronchoalveolar lavage; LC, lung cancer; RT, radiotherapy
Introduction
Lungcancer(LC)istheleadingcauseofcancer-related
deaths in the Western world [1]. LC is divided into two
maingroups: non-small celllung cancer(NSCLC) and
small cell lung cancer (SCLC). Treatment is based on
the staging of the cancer and on the performance status
of the patient. Surgery is the main treatment for limited
disease. Advanced NSCLC is mainly treated with
radiotherapy (RT) and chemoradiotherapy [2 4].
Radiation generates primary radicals by transferring
energy to certain cellular components, e.g. water [5].
Reactive oxygen species (ROS) are formed in this
process and they mediate the anti-tumour effects of
RT [6]. A delicate situation occurs at the tissue level
when oxidative stress is a desired effect against
malignant cells; yet the amount of oxidative stress
should be kept in balance to prevent permanent
damage to normal cells.
An increasing number of studies have been pub-
lished where bronchoalveolar lavage (BAL) has been
used as a window to assess the oxidative status of the
lungs, e.g. in asthma, pulmonary fibrosis, chronic
obstructive pulmonary disease (COPD) and after
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Free Radical Research, July 2009; 43(7): 646 657exposure to ozone and diesel [7 12]. However, there
are only a limited number of clinical studies involving
BAL in LC patients. Melloni et al. [13] reported
increased glutathione and reduced superoxide dis-
mutase levels in BAL fluid of LC patients compared
to non-cancer controls. The levels of vascular en-
dothelial growth factor in BAL fluid are elevated in
LC patients before and during radio-chemotherapy
[14,15]. RT raises the concentration of interleukin-6
and TGF-b1 in the BAL fluid of LC patients [16].
The respiratory tract lining fluid (RTLF) contains
a variety of antioxidant enzymes (superoxide dismu-
tase, catalase, glutathione peroxidase and glutathione
reductase), small non-enzymatic antioxidants (vita-
min C, E, A and glutathione) and other compounds
like albumin, ceruloplasmin and transferrin. RTLF
plays an important role in protecting the cells from
external oxidants, e.g. tobacco smoke and air pollu-
tants. The fluid obtained in connection with ther-
apeutic or diagnostic BAL provides a sample of the
cellular and non-cellular components from the site of
the respiratory epithelium itself [7,11,17].
To explore the RTLF status and the systemic
oxidative stress, we determined the levels of a number
of antioxidants (ascorbic acid, vitamin E, alpha- and
gamma-tocopherol, urate, thiols, glutathione), the
total antioxidant capacity (TRAP) and several para-
meters of oxidative and nitrosative stress (proteins,
oxidized proteins, TBARS, conjugated dienes, nitrite,
nitrite nitrate) in BAL fluid and blood of lung
cancer patients and non-cancer controls. These
markers were evaluated at baseline and during and
after RT of lung cancer. We also examined whether
these markers predict adverse events, response to
treatment and overall survival of LC patients.
Material and methods
Study groups and procedures
Thirty-six histologically or cytologically confirmed
LC patients and 36 non-cancer controls were en-
rolled at the Department of Respiratory Medicine.
The inclusion criteria for both groups were: Kar-
nofsky performance status of ]70% and no serious
acute infection. The exclusion criteria were: serious
cardiac, metabolic or hepatic disease, forced expira-
tory volume in 1 s (FEV1)51.5 l, regular allopurinol
or acetylcystein medication or gout. The controls
were recruited among the patients referred for
bronchoscopy due to prolonged cough. The charac-
teristics of the two groups are shown in Table I.
Neither the patients nor the controls had taken
vitamin or herbal supplementation within 3 months
prior to the study. Data on smoking, other diseases,
medication and symptoms were collected on a stan-
dardized questionnaire modified from the ATBC
(Alpha-Tocopherol, Beta Carotene Cancer Prevention
Study) study [18]. Pre-treatment evaluation of the LC
patients consisted of a physical examination, chest
radiography, bronchoscopy, chest and upper abdom-
inal computerized tomography, urinanalysis, full blood
count and serum chemistry. Abdominal sonography
and bone scintigraphy were performed as needed.
Smokers were defined either as current smokers or as
smokers who had stopped smoking less than 6 months
previously, ex-smokers as subjects who had stopped
smoking more than 6 months ago and non-smokers
had never smoked. The lifetime cigarette consumption
was expressed as pack years (cigarette packs smoked/
day years smoked).
This study was conducted according to the guide-
lines of the Declaration of Helsinki. Written informed
consent was obtained from each participant to a study
protocol approved by the ethics committee of the
Tampere University Hospital.
Bronchoscopy and BAL samples
All patients and controls underwent bronchoscopy
and BAL as a diagnostic procedure. Patients receiving
RT underwent a second bronchoscopy and BAL
2 weeks after start of RT (at 18 22 Gray). During
RT BAL was performed on the irradiated lung and
on the same segment as at diagnosis, if possible.
All bronchoscopies were carried out by the same
experienced bronchoscopist (SS) according to
Table I. Characteristics of lung cancer patients and controls.
Values are means (SD; range) or numbers (percentages).
Lung cancer patients
(n 36) Controls (n 36)
Age (years) 66.9 (9.1; 47 82) 50.8 (9.9; 18 75)
Males 29 (80.6) 16 (44.4)
BMI (kg/m
2) 23.7 (3.2; 17.0 31.8) 26.3 (5.2; 18.5 39.2)
FEV1 (% of
predicted)
a
74.1 (11.8; 58.0 94.0) 89.4 (11.5; 65 108)
Smoking
Non-smokers 2 (5.6) 18 (50.0)
Ex-smokers 10 (27.8) 6 (16.7)
Smokers 24 (66.7) 12 (33.3)
Pack-years of
smokers or
ex-smokers
35.3 (23.0; 5.0 96) 28.5 (17.7; 7.5 68)
Histology
Squamous
cell cancer
33 (91.7)
Adenocarcinoma 1 (2.8)
Small cell cancer 2 (5.6)
Stage of lung cancer
IB 1 (2.8)
IIIA 6 (16.7)
IIIB 12 (33.3)
IV 17 (47.2)
Karnofsky performance status
70 4 (11.1) 0 (0)
80 8 (22.2) 0 (0)
90 15 (41.7) 3 (8.3)
100 9 (25.0) 33 (91.7)
an 13 and n 20.
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the subjects were awake and breathed spontaneously.
All subjects received pre-medication with intramuscu-
lar atropine sulphate (0.7 mg) and topical lidocain
anaesthesia to the nasal airways and posterior phar-
yngeal wall. A flexible bronchoscope was wedged into
the segmental or subsegmental level of the left upper
lobe or right middle lobe. Five-times 20 ml of sterile
saline (378C) mixed with Addiphos buffer (4% v/v,
Fresenius Kabi, Uppsala, Sweden) was instilled
through the bronchoscope. The fluid was immediately
recovered by gentle suction after each instillation
[19,20]. Due to ethical reasons, BAL was performed
only on one side of the lungs at each bronchoscopy.
The BAL fluid samples were immediately pro-
tected from light and put on ice. The samples were
centrifuged at 500 rpm for 15 min at 48C and stored
at  708C until analysis. The samples for ascorbic
acid analysis were mixed (1:10) with 5% meta-
phoshoric acid and isoascorbate. Cells were stained
with the May-Gru ˝nwald Giemsa (MGG) and Papa-
nicolau stains and fixed with 50% ethanol.
Blood samples
All patients underwent laboratory testing at baseline.
In addition to oxidative stress markers the tests
included: full blood count, alkaline phosphatase,
alanine transferase, aspartate transferase, creatinine,
serum C- reactive protein, sodium and potassium.
The blood samples for oxidative stress markers
were taken as follows: Peripheral venous blood
samples were collected using a Venoject blood
collection system (Terumo, Leuven, Belgium). Two
tubes (10 ml each) of blood were obtained, one for
serum preparation and one for plasma analysis. The
serum samples were collected into sterile tubes and
the samples intended for plasma analysis were col-
lected to cooled, sterile tubes containing ethylenedia-
minetetraacetic acid (EDTA). The samples were
protected from light and centrifuged at 2800 g for
10 min after which the plasma specimen for ascorbic
acid analysis was mixed (1:10) with 5% metaphosho-
ric acid and isoascorbate. The samples were frozen
immediately and stored at  708C until analysis.
Blood samples were collected of all patients at
baseline. The second set of blood samples coincided
with second bronchoscopy during RT at 18 22 Gray
and the third 3 months after start of RT.
Radiotherapy
Twenty out of 36 patients received RT as a treat-
ment. Sixteen patients received RT based on three-
dimensional CT-based treatment planning by Cad
Plan (version 6.23, Varian Medical Finland, Varian
Medical Systems Inc). Fractions (fr), usually of 2 Gray
(Gy), were given five times a week. Four patients
received palliative RTwith two anterior-posterior fields
3 Gy/fr five times a week. The planning target volume
(PTV) contained the primary tumour and adjacent
lymph nodes with adequate margins. RT with 18 MV
photons was applied by a linear accelerator (Varian
Clinac 2100 C/D, Varian Medical Systems Inc., Palo
Alto, CA) at the Radiotherapy Unit of the Tampere
University Hospital. The mean radiation dose deliv-
ered was 46.9 Gray (range 30.0 60.0 Gy).
Analyses
BAL fluid and plasma thiols. Thiols in 400 ml of BAL
fluid or 100 ml of plasma were determined with
Ellman’s reagent as described [21]. The coefficient
of variation between the series was 6.6%.
BAL fluid and plasma ascorbic acid. BAL and plasma
ascorbic acid were determined in metaphosphoric
acid (5%) stabilized samples by HPLC with electro-
chemical detection [22]. The coefficient of variation
between the series was 5.5%.
BAL fluid and serum urate. BAL and serum urate were
analysed by an enzymatic method (Thermo Fisher
Scientific Oy, Vantaa, Finland) using uricase, perox-
idase and ascorbate oxidase. The coefficient of
variation between the series varied from 1.4 2.3%
and the accuracy (bias) was  1.4%, as assessed by
an external quality programme (Labquality Ltd,
Helsinki, Finland).
BAL fluid and plasma nitrite and Nox. Concentrations
of nitrite and Nox (nitrite nitrate) were measured
by the ozone-chemiluminescence method [23,24].
The detection limit for nitrite was 0.2 mmol/L and
1.5 mmol/L for Nox.
Plasma tocopherols. Alpha- and gamma-tocopherols
were analysed as described [25,26]. The coefficient of
variation between the series was 5.2%. The results are
expressed as mg/L.
Serum vitamin E. Serum vitamin E was measured by
chromatographic methods as described [27].
Plasma glutathione. Total glutathione in the plasma
(GSSG GSH) was determined by an enzymatic
recycling reaction [28].
Serum protein oxidation, diene conjugation, TBARS,
TRAP. Protein carbonyl determinations were carried
out as described [29]. Two different methods (diene
conjugation, thiobarbituric acid reactive substances,
TBARS) were used to estimate serum levels of lipid
peroxides. Conjugated dienes were analysed spectro-
photometrically at 234 nm [30]. For the analyses
of TBA-reactive substances the absorbances were
measured at 535 nm [31]. The antioxidant potential
648 M. Crohns et al.of the samples (total peroxyl radical trapping
antioxidant potential, TRAP) was estimated by
their potency to resist 2,2?-azobis(2-amidinopropane)
(ABAP) induced peroxidation [32].
The concentrations of BAL and plasma thiols,
BAL and plasma ascorbic acid, BAL and serum
urate, BAL and plasma nitrite and Nox, serum
vitamin E, plasma glutathione, serum protein oxida-
tion, serum diene conjugation, serum TBARS and
serum TRAP are expressed as mmol/L.
Serum proteins. Serum proteins were analysed by a
colorimetric end-point measurement following the
Biuret method [33,34]. The intra-assay coefficient of
variation was 0.88% and the inter-assay 1.80%. The
results are expressed as g/L.
BAL fluid cell counts. The total cell and differential
cell counts were determined by microscopy of fixed
BAL fluid samples. BAL fluid albumin was measured
by nephelometry and proteins by colorimetry.
Evaluation of adverse events and response to treatment
During and after the RT, all adverse events were
evaluated according to the criteria of the World
Health Organization (WHO) and Lent Soma Table
[35,36]. The responses to treatment were evaluated
according to the criteria of WHO [35].
Statistics
The systemic and local oxidative stress markers were
the primary variables of the study. The results are
given as means or geometric means with 95%
confidence intervals. The distributions of some oxi-
dative stress markers were skewed to the right and
were thus logarithmically (ln) transformed before
analysis. The t-test for independent samples was
used to compare patients and controls. Since there
were differences in demographic variables, the ad-
justed comparison (ANCOVA) includes age and
FEV1 (%) as continuous covariates and gender and
smoking (smoker vs non-smoker) as random factors.
The interaction terms between the explaining factors
are not included in the multivariable models. The
group comparisons are presented as mean difference
or as a ratio (patients/controls) with 95% confidence
intervals. The within-patient changes in oxidative
stress markers were analysed with the t-test for paired
samples and ANOVA for repeated measures. Spear-
man’s and Pearson’s correlations were calculated to
express the associations between oxidative stress
markers, age and pack-years of smoking. The t-test
for independent samples was used to compare
different demographic groups (grouping by smoking,
gender, other diseases, stage of disease). The oxida-
tive stress markers at baseline were divided into
two groups (Bmedian and  median) and the
Kaplan-Meier method was applied to plot the survi-
val curves. The log-rank test was used to compare
the survival distributions. The survival times are
given as medians with 95% confidence interval. The
Mann-Whitney’s U-test was used for variables with
a non-normal distribution and the x
2-test was used
for categorical variables. p-values of less than 0.05
were considered statistically significant. The statisti-
cal analyses were performed with the SPSS (release
15.0) software (SPSS inc. Chicago, IL).
Results
Patients and controls
Thirty-six LC patients entered to the study and
36 non-cancer patients served as controls (Table I).
The diagnosis of LC was confirmed histologically in 27
of the patients and for the remaining nine patients the
diagnosis was based on class V BAL cytology and
imaging results. Twenty of the LC patients received
radiotherapy, 15 of whom underwent a second
bronchoscopy during RT. Two patients were treated
only by surgery after the diagnosis, six received various
chemotherapy regimens and nine received sympto-
matic treatment. Of these 16 patients only baseline
samples were obtained.
The final diagnosis for the controls showed that
none of them had cancer, three (8%) had asthma, two
(6%) chronic bronchitis and mild chronic obstructive
pulmonary disease (COPD), one (3%) COPD and
one (3%) control patient was operated on for a
benign papilloma. All other control patients (80%)
were diagnosed as having idiopathic prolonged cough
and had no further treatment.
The patient and control groups differed with respect
to some major main characteristics (Table I) and thus
the results were adjusted for age, FEV1,g e n d e ra n d
smoking. There were no significant associations
between any of the other diseases (cardiac disease,
diabetes, chronic arrhythmia or rheumatic disease)
with regard to oxidative stress marker levels.
The mean instilled BAL fluid volume was 111 ml
for LC patients and 101 ml for controls (p 0.033);
the recovery volumes were 55.3 ml and 67.3 ml
(p 0.005), respectively, at first bronchoscopy.
There were no statistically significant differences in
the total cell counts of BAL fluid samples between the
groups, but LC patients had a higher neutrophil
count than controls (3% vs 1%; p 0.002). There
were no significant complications during or after the
bronchoscopies.
Systemic oxidative stress markers at baseline
The LC patients had significantly higher levels of urate
(241 mmol/L, 95% CI 210 272 mmol/L vs 116 mmol/L,
95% CI 91 141 mmol/L, pB0.001) and nitrite
(0.591 mmol/L, 95% CI 0.548 0.634 mmol/L vs
Oxidative stress during lung cancer radiotherapy 6490.181 mmol/L, 95% CI 0.136 0.225 mmol/L, pB
0.001) than the controls at baseline. The LC patients
had significantly lower levels of thiols (303 mmol/L,
95% CI 283 322 mmol/L vs 364 mmol/L, 95% CI 338 
390 mmol/L, pB0.001) and oxidized proteins (2.85
mmol/L, 95% CI 2.46 3.23 mmol/L vs 4.30 mmol/L,
95% CI 4.06 4.55 mmol/L, pB0.001) than the con-
trols at baseline.
After adjustment for age, FEV1,g e nd e ra n ds mo k i n g,
significant differences persisted for urate, nitrite and
oxidized proteins (p 0.016, pB0.001 and p 0.027,
respectively), whereas significance was lost for thiol
levels (p 0.651) (Figure 1).
There were no significant differences in ascorbate
(73.3 vs 78.3 mmol/L, p 0.529), glutathione
(geometric mean 0.79 vs 0.89 mmol/L, p 0.636),
vitamin E (26.7 vs 29.8 mmol/L, p 0.264), conju-
gated dienes (51.8 vs 54.8 mmol/L, p 0.420), TRAP
(947 vs 963 mmol/L, p 0.751), TBARS (4.64 vs
4.60 mmol/L, p 0.855), Nox (28.6 vs 26.5 mmol/L,
p 0.482) or proteins (69.0 vs 72.0 g/L, p 0.054)
between the two groups at baseline (Table II).
Local oxidative stress markers in BAL fluid at baseline
Cancer patients had significantly higher levels of
urate (geometric mean 11.18 mmol/L, 95% CI
7.76 16.11 mmol/L vs 6.45 mmol/L, 95% CI 4.77 
8.72 mmol/L, p 0.019) and thiols (geometric mean
4.40 mmol/L, 95% CI 2.69 7.21 mmol/L vs 1.48, 95%
CI 1.12 1.95 mmol/L, pB0.001) and lower levels of
Nox (geometric mean 0.87 mmol/L, 95% CI 0.77 
0.97 mmol/L vs 1.34 mmol/L, 95% CI 1.12 1.60
mmol/L, pB0.001) than controls at baseline. How-
ever, after adjustment for age, FEV1, gender and
smoking, significance was lost for the difference of
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Oxidative stress during lung cancer radiotherapy 651these markers between the patients and controls (p 
0.069, p 0.378 and p 0.979 for BAL urate, thiols
or Nox). Nor were there significant differences in the
levels of BAL ascorbate or nitrite between LC patients
and controls (0.53 mmol/L vs 0.79 mmol/L, p 0.293
and 0.18 mmol/L vs 0.21 mmol/L, p 0.176, respec-
tively). The concentrations of TRAP in BAL fluid
samples were undetectable (Table II, Figure 1).
Systemic oxidative stress markers during and
after radiotherapy
Although not significant, there was a trend towards
an increase in alpha-tocopherol (6.43 vs 8.86 mg/L,
p 0.056), urate (220 vs 255 mmol/L, p 0.064) and
oxidized proteins (2.64 vs 3.29 mmol/L, p 0.088)
after 2 weeks of RT. There was also a slight, but
non-significant, reduction in glutathione, thiols,
TRAP, TBARS, proteins, Nox and vitamin E. Non-
significant increases were noted in ascorbate, gamma-
tocopherol and conjugated dienes during RT. The
levels of nitrite remained unchanged during RT
(Figure 2).
Three months after RT, the levels of urate (214 vs
280 mmol/L, p 0.044), conjugated dienes (53.4 vs
64.6 mmol/L, p 0.034) and TBARS (4.58 vs 5.64
mmol/L, p 0.004) had risen significantly. A nearly
significant increase was noted in alpha-tocopherol
(p 0.055). The changes in the levels of other
antioxidants and markers of oxidative and nitrosative
stress 3 months after RT were non-significant.
Local oxidative stress markers in BAL fluid during
radiotherapy
There was an almost significant increase in urate
(geometric mean 7.30 mmol/L vs 13.91 mmol/L,
p 0.083) and thiols (geometric mean 3.34 mmol/L
vs 4.85 mmol/L, p 0.069) after 20 Gy of RT
compared to baseline. No notable changes took place
for BAL ascorbate, nitrite or Nox during RT.
Oxidative stress markers and lung cancer stage
Higher BAL thiol (6.29 mmol/L vs 2.54 mmol/L, p 
0.063) and BAL nitrite (0.21 mmol/L vs 0.15 mmol/L,
p 0.021) levels and lower serum oxidized proteins
(2.36 mmol/L vs 3.39 mmol/L, p 0.005) and serum
TBARS (4.37 mmol/L vs 4.94 mmol/L, p 0.067)
levels were recorded in stages I III compared to stage
IV disease.
Association between oxidative stress markers, adverse
events and response to RT
Overall toxicity during RT was mild and none of the
patients experienced any serious adverse events.
Thirteen (65%) patients experienced gr I/II adverse
events during RT: esophagitis (n 9), cough (n 4),
fatigue (n 4) and fever (n 4). Five patients (25%)
developed symptomatic radiation pneumonitis. The
occurrence of adverse events during RT was not
significantly associated with any baseline oxidative
stress marker levels.
Twenty-five per cent of the LC patients achieved
complete and 56.3% partial response to RT, whereas
6.3% had no change and 12.5% had progressive
disease. The response to treatment was not signifi-
cantly associated with any baseline oxidative stress
marker levels.
Association between oxidative stress markers
and overall survival
The planned follow-up time of the patient group was
72 months. None of the patients was lost to follow-
up. At the end of the study, one patient (3%) was
alive and 35 (97%) had died. The median survival
time of the patients was 9.9 months (95% CI 5.4 
14.4 months). The survival time tended to be longer
when the patient’s baseline BAL thiol levels were
above the median concentration of 4.34 mmol/L (9.9
months vs 6.1. months, p 0.051) (Figure 3).
Associations between oxidative stress markers
and other demographics
There were no significant differences in oxidative
stress markers between smokers and non-smokers
among the patients. However, among the controls,
smokers had significantly higher levels of BAL thiol
(2.73 vs 1.47 mmol/L, p 0.022), serum urate (177
vs 106 mmol/L, p 0.035), serum TBARS (5.06 vs
4.36 mmol/L, p 0.042) and serum nitrite (0.25 vs
0.14 mmol/L, p 0.017) and lower levels of plasma
ascorbate (59 vs 88 mmol/L, p 0.011). Among the
controls, the number of pack years smoked correlated
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Figure 2. The mean levels of serum conjugated dienes and serum
urate (mmol/L) at baseline (I), after 2 weeks of radiotherapy (II)
and 3 months after radiotherapy (III).
652 M. Crohns et al.negatively with plasma ascorbic acid (R  0.452,
p 0.014).
There was a trend favouring an association be-
tween weight loss prior to diagnosis and overall
survival, but this finding lacked statistical significance
(p 0.769). If patients had lost weight less than 2 kg
prior to lung cancer diagnosis, the median overall
survival was 12.4 months (95% CI 9.2 15.6 months);
if weight loss was 3 5 kg median survival was 8.7
months (95% CI 4.0 13.4 months) and if weight loss
was more than 5 kg, median survival was 3.8 months
(95% CI 0 11.5 months).
There were significant positive correlations between
BAL ascorbic acid and plasma ascorbic acid (R 
0.342, p 0.005), BAL thiols and both serum urate
(R 0.481, p 0.001) and serum alpha-tocopherol
(R 0.714, p 0.031) and a negative correlation
between plasma ascorbic acid and both plasma and
BAL thiols at baseline (R  0.446, p 0.008 and
R  0.377, p 0.052, respectively) (Figure 4).
Discussion
This study shows that lung cancer is associated with
enhanced circulating concentrations of urate and
nitrite (pB0.001 for both), which is in accordance
with previous findings [37,38]. Urate, which is the
end product of purine metabolism, is one of the
major antioxidants in human plasma and it may play
an essential role in protecting cells against free-radical
induced damage. Thus, elevated levels of urate may
signify a compensatory mechanism to oxidative stress
[39]. It is also shown that both cancer and RT are
associated with increased oxidative damage to DNA
[40,41] and thus hyperuricemia might be also partly
due to increased purine metabolism through the
effects of xanthine oxidase as a consequence of
RNA-DNA breakdown [42].
Nitric oxide (NO) is involved in many physiologi-
cal processes and has an extremely short half-life
[43]. However, the blood NO level does not
necessarily reflect the NO status of the tissues. In
plasma and other physiological fluids NO is oxidized
to nitrite, whereas in the whole blood NO and nitrite
are oxidized to nitrate [44]. Increased production of
nitric oxide may protect the cells from oxidative stress
and this might explain the elevated levels of nitrite
among LC patients compared to controls (pB0.001,
Table II) [45]. On the other hand, production of a
potent oxidant and cytotoxic molecule, peroxynitrite
in the reaction of NO with the superoxide anion may
lead to increased biochemical reactivity and a wide
range of damaging effects.
Increased free radical production, decreased activ-
ity of the antioxidant defense mechanisms or en-
hanced consumption of antioxidants lead to oxidative
stress [46]. The total antioxidant capacity has been
used to measure oxidative stress in whole body
Figure 3. Kaplan-Meier survival curves for patients with baseline
BAL thiols  4.34 mmol/L (n 14) vs patients with BAL thiols
B4.34 mmol/L (n 14). Log-rank test p 0.051.
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Oxidative stress during lung cancer radiotherapy 653[45,47]. In a previous study we reported significantly
lower total peroxyl radical trapping antioxidant po-
tential (TRAP) levels in LC patients compared to
healthy controls [48]. Although also the present study
noted decreased levels of TRAP in LC patients
compared to controls (Table II), the difference
between the two groups was not significant. This is
in agreement with a previous study [49]. Yet, the
known components of TRAP, besides urate, tended
to be lower in the LC group than controls: protein
SH-groups (thiols) (pB0.001, p 0.651 after adjust-
ment for age, FEV1, gender and smoking), ascorbic
acid (p 0.53, p 0.753 after adjustment) and
vitamin E (p 0.26, p 0.121 after adjustment).
We also recorded a significant positive correlation
between plasma TRAP and serum urate, which
corroborates a previous similar observation [50].
The antioxidant levels in BAL fluid of lung cancer
patients have not been the subject of very much
research. After adjustment for age, FEV1, gender and
smoking, no significant differences were noted be-
tween LC patients and non-cancer controls in BAL
fluid oxidative stress markers, although LC patients
tended to have higher levels of BAL urate (p 
0.069). As bronchoscopy was performed on the
control patients because of prolonged cough, it is
possible that they had altered mucus secretion due to
hypertrophy in mucus secreting glandula caused by
chronic, hyperplastic bronchitis appearing as pro-
longed cough. This may partly explain why no
differences were seen in BAL oxidative stress markers
between LC patients and non-cancer controls. The
levels of BAL ascorbate seen in this study are in
conformity with previous studies [7,12,51]. The
levels of BAL urate are higher than reported in
some previous studies [7,12,51]; however, in align-
ment with the levels obtained of lung transplant
recipients [52]. The method we used to analyse
BAL and plasma thiols measures all small molecular
weight as well as protein thiols, which explains the
higher levels compared to studies reporting only
glutathione/reduced glutathione levels [12,13].
We observed a tendency of BAL urate (p 0.083)
and thiols (p 0.069) to rise during RT, a finding not
reported previously. Although not significant, the
levels of plasma alpha-tocopherol (p 0.056), serum
urate (p 0.064) and serum oxidized proteins (p 
0.088) tended to increase after 2 weeks of RT. The
elevated levels of urate both locally and systemically
during RT might be attributed to enhanced cell
necrosis following RT; it is known that urate is
released from dying cells [46]. This increase in urate
during RT is in accordance with previous findings
[48]. It has been shown that RT also produces thiol
radicals, which can react with ascorbic acid or NO
[46]. The elevated levels of BAL urate might also be
attributed to the movement of urate onto the lung
surface to protect against oxidative stress caused by
RT [12]. The elevation of oxidized proteins levels
during RT might be a causal factor in an early event
of oxidative endothelial cell damage and also a marker
of enhanced RT-related oxidative stress [53]. Aside
from urate, the changes in BAL fluid antioxidant
levels during RT seem to be independent of systemic
changes in these markers.
Lipid peroxidation might be one of the main causes
of damage during RT and previous studies have
reported increased lipid peroxidation marker levels
during RT [54,55]. RT is also known to cause
oxidation of membrane protein SH- groups, which
may explain the present finding of elevated levels of
serum oxidized proteins and BAL thiols during RT
[56].
Thiobarbituric-acid-reactive substances (TBARS)
are considered to be markers of lipid peroxidation in
tissues and the plasma, although rather unspecific
[46,57 59]. During the early phase of lipid peroxida-
tion the double bonds of polyunsaturated fatty acids
(PUFAs) are rearranged and conjugated dienes are
formed. Conjugated dienes have been widely studied
as an index of lipid peroxidation and are less sensitive
to the compensatory antioxidant mechanisms than
the other lipid peroxidation markers [59,60]. The
significantly elevated levels of serum conjugated
dienes (p 0.034) and TBARS (p 0.004) 3
months after RT imply that the main antioxidants
scavenger systems are consumed during RT, leading
to enhanced lipid peroxidation after RT [45]. Pre-
vious studies have shown that the onset of lipid
peroxidation caused by RT may be delayed [61]. In
the present study lower baseline serum TBARS levels
were measured in limited disease (stages I/II/III)
compared to extensive disease (stage IV, p 0.067),
which is supported by a previous study reporting
reduced plasma malondialdehyde concentration with
decreasing tumour size [62].
To our knowledge, this is the largest study so far to
evaluate different antioxidants and parameters of
oxidative and nitrosative stress in lung cancer patients
and during RT for lung cancer. No previous clinical
follow-up studies have been performed that have
recorded oxidative stress markers in relation to
response to RT and overall survival of LC patients.
We found no associations between any of the oxida-
tive stress marker baseline levels and adverse events
during or after RT or response to treatment. How-
ever, a borderline significant association was recorded
between higher BAL thiol levels and longer overall
survival. A recent study observed that head and neck
carcinoma patients who have a higher than median
concentration of glutathione in plasma survive longer
[63]. Measuring also the ratio of oxidized glutathione
to reduced glutathione in this study would have
added beneficial information to the hypothesis that
increased glutathione is associated with overall survi-
val; this is one limitation of our finding. We also noted
654 M. Crohns et al.that the LC stage was associated with baseline BAL
thiol levels: higher local thiol levels were seen in stage
I III LC compared to stage IV LC (p 0.063).
Although these associations are of borderline statis-
tical significance, it is also possible that the longer
survival of some of the patients in this study is related
to limited stage of the disease. Obviously, larger
studies are needed to discriminate cause and effect
in this respect.
Conclusions
This study supports strongly the hypothesis that LC
is associated with increased oxidative stress. The
findings suggest that antioxidant responses may serve
as a protective mechanism against production of ROS
during RT. The cellular damage caused by RT may
also result in release of intracellular antioxidative
substances. This study indicates that oxidative stress
caused by RT may be counterbalanced by local lung
antioxidant systems; however, notable lipid peroxida-
tion does occur after RT. None of the examined
oxidative stress markers prognosticated adverse
events during RT or the response to treatment.
However, the results imply that BAL thiols may be
associated with overall survival of LC patients.
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